TD2's highly specialized oncology drug development team enlists an integrated suite of cutting-edge tools built around cellular pathway interrogation, combination strategies, and the identification of mutationalcontexts to inform clinical development plans.

TD2's preclinical efforts focus on: Good Laboratory Practice safety/tolerability, in vitro assays, tumor xenograft models, primary tumormodels, orthotopic tumor models, and isogenic cell lines.

The preclinical team has extensive experience working with all types of molecules, including small molecules, biologics (immunoconjugates, peptides, antibodies, siRNAs and miRNAs), and is well equipped to execute studies to demonstrate efficacy in both single agent and combination settings.

A dedicated project manager is assigned to every preclinical study to provide regular updates, facilitate the flow of information, and oversee the implementation of mid-study changes.